Medicare utilization — REFAT BARIDI (MD)
Calendar year 2023 · data refreshed 2026-05-27
| HCPCS | Description | Services | Beneficiaries | Allowed | Payment |
|---|---|---|---|---|---|
| Q0138 | Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | 118,830 | 67 | $0 | $46,000 |
| J9263 | Injection, oxaliplatin, 0.5 mg | 19,200 | 11 | $0 | $1,105 |
| J9271 | Injection, pembrolizumab, 1 mg | 18,200 | 12 | $0 | $788,226 |
| J0897 | Injection, denosumab, 1 mg | 17,940 | 119 | $0 | $311,399 |
| Q5106 | Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units | 6,240 | 39 | $0 | $39,533 |
Service volume and Medicare payment amounts do not indicate quality of care, patient outcomes, or fraud. Data reflects Medicare fee-for-service only.
Source: CMS public data · Not endorsed by CMS · Beneficiary counts under 11 are suppressed in source data ·